Terms: = Bone cancer AND MYCN, N-myc, 4613, ENSG00000134323, NMYC, MODED, ODED AND Prognosis
67 results:
1. Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance.
Banerjee D; Boboila S; Okochi S; Angelastro JM; Kadenhe-Chiweshe AV; Lopez G; Califano A; Connolly EP; Greene LA; Yamashiro DJ
Cancer Res Commun; 2023 Dec; 3(12):2518-2530. PubMed ID: 38014922
[TBL] [Abstract] [Full Text] [Related]
2. Stage 4N neuroblastoma before and during the era of anti-G
Kushner BH; LaQuaglia MP; Cardenas FI; Basu EM; Gerstle JT; Kramer K; Roberts SS; Wolden SL; Cheung NV; Modak S
Int J Cancer; 2023 Dec; 153(12):2019-2031. PubMed ID: 37602920
[TBL] [Abstract] [Full Text] [Related]
3. Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group.
Wieczorek A; Stefanowicz J; Hennig M; Adamkiewicz-Drozynska E; Stypinska M; Dembowska-Baginska B; Gamrot Z; Woszczyk M; Geisler J; Szczepanski T; Skoczen S; Ussowicz M; Pogorzala M; Janczar S; Balwierz W
BMC Cancer; 2022 Jun; 22(1):701. PubMed ID: 35752779
[TBL] [Abstract] [Full Text] [Related]
4. Immune contexture of paediatric cancers.
Thakur MD; Franz CJ; Brennan L; Brouwer-Visser J; Tam R; Korski K; Koeppen H; Ziai J; Babitzki G; Ranchere-Vince D; Vasiljevic A; Dijoud F; Marec-Bérard P; Rochet I; Cannarile MA; Marabelle A
Eur J Cancer; 2022 Jul; 170():179-193. PubMed ID: 35660252
[TBL] [Abstract] [Full Text] [Related]
5. Neuroblastoma: Essential genetic pathways and current therapeutic options.
Salemi F; Alam W; Hassani MS; Hashemi SZ; Jafari AA; Mirmoeeni SMS; Arbab M; Mortazavizadeh SMR; Khan H
Eur J Pharmacol; 2022 Jul; 926():175030. PubMed ID: 35605657
[TBL] [Abstract] [Full Text] [Related]
6. mycn amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.
Yue ZX; Xing TY; Zhao W; Zhao Q; Wang XS; Su Y; Gao C; Liu SG; Ma XL
Cancer Med; 2022 Apr; 11(8):1837-1849. PubMed ID: 35137546
[TBL] [Abstract] [Full Text] [Related]
7. Evaluation of circulating Dickkopf-1 as a prognostic biomarker in ovarian cancer patients.
Klotz DM; Link T; Goeckenjan M; Wimberger P; Poetsch AR; Jaschke N; Hofbauer LC; Göbel A; Rachner TD; Kuhlmann JD
Clin Chem Lab Med; 2022 Jan; 60(1):109-117. PubMed ID: 34687595
[TBL] [Abstract] [Full Text] [Related]
8. Isolated bone Recurrence of Medulloblastoma With mycn Amplification and TP53 Loss: A Case Report.
Takahashi Y; Kudo K; Ogawa K; Sato T; Kamio T; Sasaki S; Kobayashi A; Ito T; Yamamoto T; Asano K; Ohkuma H; Kurose A; Ito E; Terui K
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e593-e596. PubMed ID: 34133388
[TBL] [Abstract] [Full Text] [Related]
9. Chromosome 10 abnormality predicts prognosis of neuroblastoma patients with bone marrow metastasis.
Jiang CY; Xu X; Jian BL; Zhang X; Yue ZX; Guo W; Ma XL
Ital J Pediatr; 2021 Jun; 47(1):134. PubMed ID: 34108028
[TBL] [Abstract] [Full Text] [Related]
10. Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by mycn gene gain/amplification and remission status: a nationwide registration study in Japan.
Saito Y; Urashima M; Takahashi Y; Ogawa A; Kiyotani C; Yuza Y; Koh K; Watanabe K; Kosaka Y; Goto H; Kikuta A; Okada K; Koga Y; Fujimura J; Inoue M; Sato A; Atsuta Y; Matsumoto K
Bone Marrow Transplant; 2021 Sep; 56(9):2173-2182. PubMed ID: 33911201
[TBL] [Abstract] [Full Text] [Related]
11. Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants.
Dondero A; Morini M; Cangelosi D; Mazzocco K; Serra M; Spaggiari GM; Rotta G; Tondo A; Locatelli F; Castellano A; Scuderi F; Sementa AR; Eva A; Conte M; Garaventa A; Bottino C; Castriconi R
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795387
[TBL] [Abstract] [Full Text] [Related]
12. [CASC5 Gene Expression Changes Correlate with Targeted Mutations in Leukemia].
Bogdanov KV; Merzlikina OV; Mirolyubova YV; Girshova LL; Lomaia EG; Zaritskey AY
Mol Biol (Mosk); 2021; 55(1):139-151. PubMed ID: 33566033
[TBL] [Abstract] [Full Text] [Related]
13. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project.
Moreno L; Guo D; Irwin MS; Berthold F; Hogarty M; Kamijo T; Morgenstern D; Pasqualini C; Ash S; Potschger U; Ladenstein R; Valteau-Couanet D; Cohn SL; Pearson ADJ; London WB
Pediatr Blood Cancer; 2021 Mar; 68(3):e28794. PubMed ID: 33205902
[TBL] [Abstract] [Full Text] [Related]
14. Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs.
Aravindan N; Somasundaram DB; Herman TS; Aravindan S
Cell Biol Toxicol; 2021 Jun; 37(3):461-478. PubMed ID: 32979173
[TBL] [Abstract] [Full Text] [Related]
15. Epigenetic Targeting of
Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
[TBL] [Abstract] [Full Text] [Related]
16. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without mycn amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract] [Full Text] [Related]
17. [Clinical characteristics and prognosis of high-risk neuroblastoma with bone marrow metastasis in children].
Fan HJ; Huang C; Su Y; Wang XD; Zhou YC; Duan C; Zhao W; Zhao Q; Jin M; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Nov; 57(11):863-869. PubMed ID: 31665841
[No Abstract] [Full Text] [Related]
18. mycn amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive evaluation of context dependence of the prognostic impact of mycn amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
[TBL] [Abstract] [Full Text] [Related]
20. Killer-cell immunoglobulin-like receptor ligand mismatch cord blood transplantation in high-risk neuroblastoma.
Matsuno R; Toyama D; Akiyama K; Isoyama K; Shiozawa E; Yamamoto S
Pediatr Int; 2019 Jun; 61(6):566-571. PubMed ID: 30974480
[TBL] [Abstract] [Full Text] [Related]
[Next]
